Rep. Robert Bresnahan, Jr. Sells Off Shares of Elevance Health, Inc. (NYSE:ELV)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Elevance Health, Inc. NYSE: ELV. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $15,001 and $50,000 in Elevance Health stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Texas Instruments NASDAQ: TXN on 5/15/2025.

Elevance Health Stock Up 0.9%

Shares of NYSE ELV traded up $3.28 on Thursday, reaching $383.35. 983,285 shares of the company's stock traded hands, compared to its average volume of 1,531,447. Elevance Health, Inc. has a 12 month low of $357.45 and a 12 month high of $567.26. The business's 50 day simple moving average is $411.30 and its two-hundred day simple moving average is $400.91. The company has a market cap of $86.61 billion, a price-to-earnings ratio of 14.96, a price-to-earnings-growth ratio of 1.18 and a beta of 0.66. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71.

Elevance Health (NYSE:ELV - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The company reported $11.97 EPS for the quarter, beating analysts' consensus estimates of $10.60 by $1.37. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. The firm had revenue of $48.77 billion for the quarter, compared to analysts' expectations of $46.26 billion. As a group, equities research analysts forecast that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th will be given a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a dividend yield of 1.78%. The ex-dividend date of this dividend is Tuesday, June 10th. Elevance Health's dividend payout ratio is currently 26.69%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ELV shares. Wall Street Zen upgraded shares of Elevance Health from a "hold" rating to a "buy" rating in a research report on Thursday, March 20th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Elevance Health in a research report on Friday, March 28th. Baird R W downgraded shares of Elevance Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, April 15th. Mizuho raised their price objective on shares of Elevance Health from $455.00 to $505.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Finally, Barclays dropped their price objective on shares of Elevance Health from $522.00 to $480.00 and set an "overweight" rating for the company in a report on Monday. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $499.53.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Milestone Asset Management LLC raised its position in Elevance Health by 37.1% in the 4th quarter. Milestone Asset Management LLC now owns 1,098 shares of the company's stock valued at $405,000 after purchasing an additional 297 shares during the last quarter. Crews Bank & Trust purchased a new stake in Elevance Health in the 4th quarter valued at $34,000. Mediolanum International Funds Ltd raised its position in Elevance Health by 3.4% in the 4th quarter. Mediolanum International Funds Ltd now owns 8,608 shares of the company's stock valued at $3,167,000 after purchasing an additional 280 shares during the last quarter. Granite Harbor Advisors Inc. raised its position in Elevance Health by 5.7% in the 4th quarter. Granite Harbor Advisors Inc. now owns 4,198 shares of the company's stock valued at $1,549,000 after purchasing an additional 227 shares during the last quarter. Finally, Caprock Group LLC purchased a new stake in Elevance Health in the 4th quarter valued at $1,989,000. Hedge funds and other institutional investors own 89.24% of the company's stock.

Insider Activity at Elevance Health

In other news, CAO Ronald W. Penczek sold 443 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $415.13, for a total transaction of $183,902.59. Following the transaction, the chief accounting officer now directly owns 1,847 shares of the company's stock, valued at $766,745.11. This represents a 19.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Mark Kaye sold 4,588 shares of the stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $424.82, for a total transaction of $1,949,074.16. Following the completion of the sale, the chief financial officer now directly owns 18,977 shares in the company, valued at approximately $8,061,809.14. The trade was a 19.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.29% of the stock is owned by insiders.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.